The goal of this observational study is to learn whether an artificial intelligence system called GliomaAI-MG can help detect a specific molecular type of brain tumour called molecular glioblastoma using routine MRI scans. The study uses previously collected and fully anonymised MRI data from 1,372 patients from 13 institutions in the Cancer Imaging Archive (TCIA). The main questions it aims to answer are: * How accurately can GliomaAI-MG identify molecular glioblastoma from MRI scans? * How well does the system perform across data from different hospitals and patient groups? Researchers will use existing MRI scans and clinical information to train and test the AI system. No new scans, treatments, or hospital visits are required for participants, and all data used is fully anonymised and obtained from an existing research database. Participants will not be asked to do anything, as this study only uses previously collected imaging data.
Study Type
OBSERVATIONAL
Enrollment
1,372
Software as Medical Device (SaMD) for predicting molecular glioblastoma
Deep Learning Institute of Radiological Sciences
Mumbai, India
Diagnostic performance of GliomaAI-MG for identification of molecular glioblastoma from MRI, measured by accuracy, sensitivity, specificity, positive predictive value, negative predictive value, and area under the receiver operating characteristic curve
The diagnostic performance of the GliomaAI-MG artificial intelligence model will be assessed by comparing pre-operative MRI-based predictions of molecular glioblastoma status against post-operative (biopsy or surgery) molecular/genetic profiling results as the reference standard. Performance metrics including accuracy, sensitivity, specificity, positive predictive value, negative predictive value, and AUC will be calculated.
Time frame: Perioperative
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.